Bright Minds Biosciences Stock Today
| DRUG Stock | USD 1.16 0.07 6.42% |
Performance4 of 100
| Odds Of DistressLess than 18
|
Bright Minds is trading at 1.16 as of the 6th of October 2024. This is a 6.42 percent increase since the beginning of the trading day. The stock's lowest day price was 1.11. Bright Minds has less than a 18 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Bright Minds Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of August 2024 and ending today, the 6th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of March 2021 | Category Healthcare | Classification Health Care |
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT medicines to improve the lives of patients with severe and life-altering diseases. The company was incorporated in 2019 and is headquartered in Vancouver, Canada. Bright Minds is traded on NASDAQ Exchange in the United States.. The company has 4.46 M outstanding shares of which 105.85 K shares are currently shorted by private and institutional investors with about 0.44 trading days to cover. More on Bright Minds Biosciences
Moving together with Bright Stock
Moving against Bright Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Bright Stock Highlights
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsBright Minds can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bright Minds' financial leverage. It provides some insight into what part of Bright Minds' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Bright Minds Biosciences (DRUG) is traded on NASDAQ Exchange in USA. It is located in 19 Vestry Street, New York, NY, United States, 10013 and employs 6 people. Bright Minds is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.29 M. Bright Minds Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.46 M outstanding shares of which 105.85 K shares are currently shorted by private and institutional investors with about 0.44 trading days to cover.
Bright Minds Biosciences currently holds about 8.64 M in cash with (7.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.71.
Check Bright Minds Probability Of Bankruptcy
Ownership AllocationBright Minds Biosciences retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Bright Ownership Details
Bright Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Advisorshares Investments, Llc | 2024-06-30 | 181 K | |
| Jane Street Group, Llc | 2024-06-30 | 10.9 K | |
| Royal Bank Of Canada | 2024-06-30 | 510 | |
| Aspire Private Capital, Llc | 2024-06-30 | 100.0 | |
| Blackrock Inc | 2024-06-30 | 1.0 | |
| Renaissance Technologies Corp | 2024-03-31 | 0.0 | |
| Virtu Financial Llc | 2024-03-31 | 0.0 | |
| Ubs Group Ag | 2024-03-31 | 0.0 | |
| Hrt Financial Llc | 2024-03-31 | 0.0 |
Bright Minds Historical Income Statement
Bright Stock Against Markets
Bright Minds Corporate Management
| FCCP MD | Chief Officer | Profile | |
| Jan MSc | Interim Director | Profile | |
| Emer MBA | Consultant | Profile | |
| Gideon Shapiro | VP Discovery | Profile | |
| Ian McDonald | CEO, CoFounder | Profile |
Additional Information and Resources on Investing in Bright Stock
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Bright Minds Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.